We Are Crinetics


Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.

Read the Latest


Crinetics Announces March 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals announces March 2023 inducement grants: the stock options were granted as inducements material to eight employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Reports Fourth Quarter and Full Year 2022 Financial Results

Crinetics Pharmaceuticals reported financial results for the fourth quarter and year ended December 31, 2022

Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (SST2 Agonist)
Acromegaly (PATHFNDR-1, 2)
Carcinoid Syndrome
Congenital Hyperinsulinism (Congenital HI)
Cushing's Disease, Congenital Adrenal Hyperplasia (CAH)
PTH Antagonist, Hyperparathyroidism
Undisclosed, Polycystic Kidney
TSH Antagonist, Graves' Disease, TED
Undisclosed (Multiple), Diabetes, Obesity
Targeted Radiotherapy Spin-out | Multiple Solid-Tumor Oncology
Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (SST2 Agonist)
Acromegaly (PATHFNDR-1, 2)
Carcinoid Syndrome
Congenital Hyperinsulinism (Congenital HI)
Cushing's Disease, Congenital Adrenal Hyperplasia (CAH)
PTH Antagonist, Hyperparathyroidism
Undisclosed, Polycystic Kidney
TSH Antagonist, Graves' Disease, TED
Undisclosed (Multiple), Diabetes, Obesity
Targeted Radiotherapy Spin-out | Multiple Solid-Tumor Oncology